November 29th 2021
Late-stage cancer and poor outcomes for patients may occur as a result of low screening numbers during the COVID-19 pandemic.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Expert Illustrations & Commentaries™: Exploring the Mechanistic Rationale for Targeting FGFR2 and Pan-FGFR in CCA
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
The 14th Asia-Pacific Primary Liver Cancer Expert Meeting
July 18 - 20, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
7th Annual Live Medical Crossfire®: Hematologic Malignancies
View More
NCCN Now Recommends Breast Cancer Index for Predicting Benefit from Extended Endocrine Therapy
January 20th 2021The Breast Cancer Index assay is the only of its kind to be recommended in the National Comprehensive Cancer Network Guidelines for the treatment of breast cancer as being predictive of extended adjuvant endocrine therapy.
MammoScreen AI Tool Improves Diagnostic Performance of Radiologists in Detecting Breast Cancer
December 16th 2020This study demonstrated that the concurrent use of this new artificial intelligence tool alongside mammography improved the diagnostic performance of radiologists in the detection of breast cancer without prolonging their workflow.
Preliminary Results Suggest AB-MR Detects Breast Cancers that 3-D Mammograms May Miss
November 29th 2020This study found that abbreviated breast magnetic resonance imaging as a supplemental screening test in women with dense breasts shows an increase in cancer detection over digital breast tomosynthesis screening.
Large Study Casts Doubt on Value of CAD
May 1st 2007Computer software used to help decipher screening mammograms reduces interpretation accuracy, increases the rate of unnecessary biopsies, and offers no clear improvement in the detection of invasive breast cancer, the largest and most comprehensive community-based study of the technology has found.
MRI Finds Contralateral Breast Tumors That Were Missed by Mammography
April 1st 2007Magnetic resonance imaging (MRI) of the contralateral breast in 969 women newly diagnosed with cancer in one breast detected 30 (3.1%) contralateral breast cancers that were missed by mammography and clinical breast exam at the time of diagnosis.
Satellite Allows Digital Mammography Screening for Rural Native Americans
March 1st 2007A mobile mammography unit that links a digital mammography system with a commercial satellite service provides near real-time interpretation of breast imaging scans to Native American women on remote rural reservations
Medicare Fee Poor Proxy in Economic Analyses of Mammography
January 1st 2007A random sampling of 2.3% of the imaging centers that meet Mammography Quality Standards Act (MQSA) certification showed that the national median cash price for a screening mammogram is more than double the price that is reimbursed by Medicare.
Digital Mammography Best for Young Women With Dense Breasts
January 1st 2007New subgroup analyses from the Digital Mammographic Imaging Screening Trial (DMIST) Investigators Group confirm previous results that digital screening mammography is significantly more accurate than film screening mammography in young women with dense breasts but not in women overall.
Docetaxel and Herceptin Both Show Benefit in FinHer Trial
March 1st 2006Nine weeks of trastuzumab (Herceptin) given concurrently with single-agent docetaxel (Taxotere) or vinorelbine (Navelbine) prior to combination chemotherapy improves survival in HER2-positive breast cancer patients, compared with no trastuzumab, with the docetaxel regimen having a slight advantage over vinorelbine.
Digital Mammography More Accurate in Younger Women
October 1st 2005ARLINGTON, Virginia-Data from more than 40,000 women who underwent both digital and film mammography at 33 sites in the US and Canada show that, while the techniques have similar overall diagnostic accuracy in breast cancer screening, digital mammography is more accurate in women under the age of 50 years, women with radiographically dense breasts, and pre- or perimenopausal women.
In Fibroglandular, Dense Breasts, MRI Outperforms Mammography in Detecting Multiple, Malignant Foci
December 1st 2004MILAN, Italy-In women with fibroglandular or dense breasts, magnetic resonance imaging (MRI) is more sensitive than mammography for detection of multiple malignant foci, suggesting that a dynamic MRI examination is warranted before treatment planning in this group of patients, a team of Italian radiologists and surgeons has concluded. Yet in breasts with an almost completely fatty pattern, both techniques had comparable sensitivity, their multicenter, prospective, nonrandomized study showed. Further, while MRI achieved a 17% gain in sensitivity over mammography in detection of invasive foci, the two techniques had similar sensitivity in detection of in situ foci, and neither had a strong positive predictive value (PPV), the researchers found.
Multimillion Dollar Costs Predicted in Screening Mammography Litigation
December 1st 2002In just 10 years, the cost of screening mammography litigation in the United States could top $250 million a year, a recent analysis has found. The analysis, presented at this year’s American Roentgen Ray Society meeting in Atlanta, is based on a
Fewer Recalls With Consensus Double Read Mammograms
August 1st 2002ATLANTA-Compared with independent double reading of mammograms, consensus double reading detects slightly more cancers while significantly decreasing recall rates, thereby minimizing the anxiety that women might experience from undergoing a second mammogram, Susan Harvey, MD, said at the 102nd Annual Meeting of the American Roentgen Ray Society (abstract 63).
HHS Secretary Supports Mammogram Screening
April 1st 2002WASHINGTON-Amid continuing controversy over the effectiveness of screening mammography for breast cancer, the US Preventive Services Task Force (USPSTF) has extended its recommendations to include women between the ages of 40 and 49, after concluding that the procedure reduces breast cancer deaths.
NCI Reaffirms Guidelines for Mammography Screening
March 1st 2002BETHESDA, Maryland-The scientific conflict about whether mammography saves lives has been reignited by the decision by an independent advisory committee to rescind its support for such screening and to emphasize the uncertainty of the evidence supporting it.
Routine Mammography Screening Increases Except Among Minorities and the Elderly
January 1st 2002The number of women receiving mammograms is higher than ever, according to the results of a study conducted by the Board of Sponsors for National Breast Cancer Awareness Month (NBCAM). The study found that more women are getting
Survey Finds Women Unwilling to Pay for Immediate Mammography Results
November 1st 2001Would you pay an additional fee to get your screening mammography results right after your examination? In a random survey of 120 women, the majority said no. In fact, one-third of the women said they preferred to get their results at a later